Survival Rates After Resection for Localized Kidney Cancer: 1989 to 2004
|
|
- Bruce Rich
- 7 years ago
- Views:
Transcription
1 84 Survival Rates After Resection for Localized Kidney Cancer: 1989 to 2004 Paul Russo, MD Thomas L. Jang, MD, MPH Joseph A. Pettus, MD William C. Huang, MD Scott E. Eggener, MD Matthew F. O Brien, MD Michael E. Karellas, MD Nicholas T. Karanikolas, MD Megan A. Kagiwada, BA Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, New York. Supported by the National Institutes of Health Ruth Kirchstein National Research Service Award T32 CA (to T.L.J.). The first 2 authors contributed equally to this work. Address for reprints: Paul Russo, MD, Urology Service, Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 353 East 68th Street, New York, NY 10021; Fax: (212) ; russop@mskcc.org Received October 18, 2007; revision received January 13, 2008; accepted February 19, BACKGROUND. Mortality rates from kidney cancer have continued to rise despite increases in the detection of smaller renal tumors and rates of renal surgery. To explore the factors associated with this treatment-outcome discrepancy, the authors evaluated how changes in tumor size have affected disease progression in patients after nephrectomy for localized kidney cancer, and they sought to identify the factors associated with disease progression and overall patient survival after resection for localized kidney cancer. METHODS. In total, 1618 patients with localized kidney cancer were identified who underwent nephrectomy at Memorial Sloan-Kettering Cancer Center from 1989 to Patients were categorized by year of surgery: from 1989 to 1992, from 1993 to 1996, from 1997 to 2000, and from 2001 to Tumor size was classified according to the following strata: <2 cm, from 2 cm to 4 cm, from 4 cm to 7 cm, and >7 cm. Disease progression was defined as the development of local recurrence or distant metastases. Five-year progression-free survival (PFS) was calculated for patients in each tumor size strata according to the year of operation using the Kaplan-Meier method. The patient-, tumor-, and surgeryrelated characteristics associated with PFS and overall survival (OS) were explored using univariate analysis, and all significant variables were retained in a multivariate Cox regression analysis. RESULTS. Overall, the number of nephrectomies increased for all tumor size categories from 1989 to A tumor size migration was evident during this period, because the proportion of patients with tumors <2 cm and with tumors from 2 cm to 4 cm increased, whereas the proportion of patients with tumors >7 cm decreased. One hundred seventy-nine patients (11%) developed disease progression after nephrectomy. Sixteen patients (1%) developed local recurrences, and 163 patients (10%) developed distant metastases. When 5-year PFS was calculated for each tumor size strata according to 4-year cohorts, trends in PFS did not improve or differ significantly over time. Compared with historic cohorts, patients in more contemporary cohorts were more likely to undergo partial nephrectomy rather than radical nephrectomy and were less likely to undergo concomitant lymph node dissection and adrenalectomy. Multivariate analysis demonstrated that pathologic stage and tumor grade were associated with disease progression, whereas patient age and tumor stage were associated with overall patient survival. CONCLUSIONS. Despite an increasing number of nephrectomies and a size migration toward smaller tumors, trends in 5-year PFS and OS did not improve or differ significantly over time. These findings require further research to identify causative mechanisms, and they argue for the consideration of active surveillance for patients who have select renal tumors and a re-evaluation of the current treatment paradigm of surgically removing solid renal masses on initial detection. Cancer 2008;113: Ó 2008 American Cancer Society. KEYWORDS: adrenalectomy, lymph node dissection, nephrectomy, overall survival, pathologic tumor classification, progression-free survival, tumor size. ª 2008 American Cancer Society DOI /cncr Published online 9 May 2008 in Wiley InterScience (
2 Survival After Resection of Kidney CA/Russo et al. 85 Kidney cancer is the third most common genitourinary tumor, with 51,190 new cases and 12,890 deaths estimated for Incidence rates have increased steadily since the 1970s, in part because of the widespread use of noninvasive imaging modalities, such as ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI). 2,3 Single-center, multi-institutional, and national incidence trends have noted a higher proportion of kidney cancers diagnosed at smaller tumor sizes and at earlier, presymptomatic stages. 2,4-8 Furthermore, the rising incidence of kidney cancer largely has been attributed to an increase in small kidney tumors. 9 Despite these findings and the concurrent increases in rates of renal operations for small renal masses that presumably are curable, kidney cancer mortality rates, paradoxically, have continued to rise. 9 To explore the factors associated with this treatment-outcome discrepancy, we sought to describe the changes in tumor size of localized kidney cancers in patients who presented at our institution from 1989 to 2004, to evaluate the impact of size migration on progression-free survival (PFS) trends after nephrectomy for localized disease, to describe trends in surgery-related and tumor-related characteristics, and to identify patient demographic and clinical characteristics associated with disease progression and overall survival (OS). MATERIALS AND METHODS Patients and Variables From January 1989 to December 2004, we identified 1618 patients who underwent radical nephrectomy (n ) or partial nephrectomy (n 5 568) for clinically localized kidney cancer at Memorial Sloan- Kettering Cancer Center. Pathologic tumor size was classified according to the following strata: <2 cm, from 2 cm to 4 cm, from 4 cm to 7 cm, and >7 cm. Patients were categorized by year of operation according to the following 4-year cohorts: from 1989 to 1992, from 1993 to 1996, from 1997 to 2000, and from 2001 to Tumor stage was determined according to the 2002 American Joint Committee on Cancer staging system. 10 All pathologic subtypes of renal cell carcinoma were included. Fuhrman tumor grade was defined as the worst grade within a tumor. Data regarding patient age, sex, race, tumor laterality, histology, year of surgery, type of surgery, surgery approach, whether patients underwent concomitant adrenalectomy, and disease progression status were available for all 1618 patients. Data concerning surgical margins and whether patients underwent concomitant lymph node dissection at the time of nephrectomy were unavailable in 24 patients and 14 patients, respectively, from the 1989 to 1992 cohort. Progression was defined as the development of local recurrence or distant metastases. Patients who had bilateral masses at diagnosis were excluded. Metachronous disease in the contralateral kidney was not considered a recurrence. Statistical Analysis Summary statistics were described using frequencies and proportions for categorical variables. We used chi-square tests as appropriate to examine whether select demographic or clinical patient characteristics were associated with tumor size. PFS was defined as the time from nephrectomy to disease progression. OS was defined as the time from nephrectomy to the date of death. Patients were censored at the date of the last follow-up if they were free of disease (when determining PFS) or if they were alive (when determining OS). The median follow-up after surgery was 50.4 months (interquartile range, 61.3 months). Fiveyear PFS rates were calculated for patients in each tumor size strata, according to the year of surgery, using the Kaplan-Meier method, and trends in PFS were compared using the log-rank test. Patient-, tumor-, and surgery-related characteristics that were associated with PFS and OS were explored first using univariate analysis, and all significant variables were retained subsequently in a multivariate Cox regression analysis. P values were 2-sided and were considered statistically significant at <.05. All statistical analyses were performed using Stata 8.2 software (Stata Corp., College Station, Tex). RESULTS Patient-, Tumor-, and Surgery-related Characteristics at the Time of Nephrectomy Demographic and clinical characteristics of cohort members are shown in Table 1 according to tumor size. There were no significant differences among tumor size groups with respect to patient age or tumor laterality. Across all tumor size strata, >85% of patients were white (P 5.019), and the majority of patients (66% 73%) had clear cell tumor histology (P 5.002). Larger tumor size was associated with higher Fuhrman grade. Patients who had smaller tumors were more likely to undergo partial nephrectomy than patients who had larger tumors. For instance, among patients with tumors that measured <2 cm and tumors that measured from 2 cm to 4 cm, 82% and 55%, respectively, underwent partial nephrectomy (P <.0001).
3 86 CANCER July 1, 2008 / Volume 113 / Number 1 TABLE 1 Demographic and Clinical Characteristics of 1618 Patients With Localized Kidney Cancer Who Underwent Nephrectomy at Memorial Sloan-Kettering Cancer Center From 1989 to 2004 According to Tumor Size Tumor size, cm <2 (n5 167) 2-4 (n 5 632) >4-7 (n 5 453) >7 (n5 366) Characteristic % of patients % of patients % of patients % of patients P Patient related Mean age SD, y Sex.548 Men Women Race.019 White Black Other Tumor related Tumor laterality.988 Right Left Tumor classification <.0001 T T T T Tumor grade < Tumor histology.002 Clear cell Papillary Chromophobe Unclassified Collecting duct Surgery related Surgery y < Type of surgery Radical nephrectomy <.0001 Partial nephrectomy Surgical approach <.0001 Open nephrectomy Laparoscopic nephrectomy Surgical margin status.004 Negative Positive Not available Adrenalectomy <.0001 Yes No Lymph node dissection <.0001 Yes No Not available SD indicates standard deviation.
4 Survival After Resection of Kidney CA/Russo et al. 87 FIGURE 2. Open bars indicate radical nephrectomy; solid bars, partial nephrectomy. FIGURE 1. (a) Tumor size distribution according to year of surgery. Line A indicates tumors <2 cm; line B, tumors from 2 cm to 4 cm; line C, tumors from >4 cm to 7 cm; line D, tumors >7 cm. (b) Tumor classification (T) distribution according to year of surgery. Line A indicates T1a tumors; line B, T1b tumors; line C, T2 tumors; line D, T3a tumors; line E, T3b tumors; line E, T3c tumors; line G, T4 tumors. Patients who had larger tumors were more likely to undergo concomitant adrenalectomy and/or lymph node dissection. For example, among patients who had tumors that measured <2 cm, 11% and 8% underwent adrenalectomy and lymph node dissection, respectively, compared with 75% and 60%, respectively, of patients who had tumors that measured >7 cm (adrenalectomy, P <.0001; lymph node dissection, P <.0001). Trends in Tumor- and Surgery-related Characteristics Tumor size and tumor stage distributions Figure 1a,b demonstrates the changes in tumor size and tumor stage distributions, respectively, of localized kidney cancers from 1989 to A tumor size migration was evident during this period (Fig. 1a), because the proportion of patients with tumors that measured <2 cm and tumors that measured from 2 cm to 4 cm increased 9% and 11%, respectively, whereas the proportion of patients with tumors that measured from 4 cm to 7 cm and tumors that measured >7 cm decreased 5% and 15%, respectively, between the periods 1989 to 1992 and 2001 to 2004 (P <.0001). Similarly, a stage migration toward T1a lesions was observed (Fig. 1b). For example, the proportion of patients with T1a tumors increased 23%, whereas the proportion of patients with T1b and T2 tumors decreased 3% and 8%, respectively, between the periods 1989 to 1992 and 2001 to 2004 (P <.0001). However, the correlation between tumor size and pathologic tumor stage was imperfect. Among patients with tumors that measured <2 cm and tumors that measured from 2 cm and 4 cm, 93% and 90%, respectively, were classified as pathologic T1a tumors (data not shown). Rates of renal surgery Figure 2 demonstrates the changes in the number of radical and partial nephrectomies performed from 1989 to The number of renal operations (radical and partial nephrectomy) increased with time. For patients with localized tumors who presented for nephrectomy from 1989 to 1992, radical nephrectomy comprised 88% of renal operations, whereas partial nephrectomy comprised 12%. In the later years, partial nephrectomy became the predominant renal operation performed at our institution for localized kidney tumors. For instance, partial nephrectomy comprised 53% of all renal operations from
5 88 CANCER July 1, 2008 / Volume 113 / Number 1 FIGURE 3. (a) Tumor histology according to year of surgery. Line A indicates clear cell histology; line B, papillary histology; line C, chromophobe histology; line D, unclassified histology; line E, collecting duct histology. (b) Proportion of patients who underwent lymphadenectomy according to year of surgery. Line A indicates yes; line B, no; line C, unavailable. (c) Proportion of patients who underwent adrenalectomy according to year of surgery. Line A indicates yes; line B, no. (d) Fuhrman tumor grade according to year of surgery. Line A indicates grade 1; line B, grade 2; line C, grade 3; line D, grade to 2004 compared with 47% for radical nephrectomy. Renal operations were performed laparoscopically first in Laparoscopic radical nephrectomies comprised 1.9%, 14.8%, and 6.7% of renal operations performed in 2002, 2003, and 2004, respectively, whereas laparoscopic partial nephrectomies comprised 0.6%, 2.1%, and 3.3%, respectively (data not shown). Other tumor- and surgery-related characteristics Tumor histology did not vary significantly with time (Fig. 3a). Clear cell tumors predominated in each time era, approximating 70% of all localized tumors, irrespective of the year of surgery. Tumors with papillary histology comprised 13% to 19% of all tumors, depending on the year of surgery, followed by chromophobe tumors, which comprised 6% to 13% of all tumors (P 5.099). In general, patients who underwent nephrectomy in more contemporary eras were less likely to undergo a concomitant lymph node dissection (Fig. 3b) and adrenalectomy (Fig. 3c) compared with cohorts from earlier eras. When excluding historic data with incomplete ascertainment (ie, the cohort), 37% and 73% of patients from the 1993 to 1996 cohort underwent lymphadenectomy and adrenalectomy, respectively, compared with 27% and 23% of patients, respectively, from the 2001 to 2004 cohort.
6 Survival After Resection of Kidney CA/Russo et al. 89 Disease Progression Overall, 179 patients (11%) developed disease progression after nephrectomy, including 16 patients (1%) who developed an isolated local recurrence and 163 patients (10%) who developed distant metastasis. Among the patients who underwent radical nephrectomy, 161 of 1050 patients (15%) had disease progression compared with 18 of 568 patients (3%) who had disease progression after partial nephrectomy (P <.0001) The PFS for the entire cohort of patients who presented with localized renal cortical tumors, stratified by 4-year cohorts, is shown in Figure 4a. The actuarial 5-year PFS rates after nephrectomy (Table 2) were 88%, 84%, 89% and 90% for patients treated from 1989 to 1992, from 1993 to 1996, from 1997 to 2000, and from 2001 to 2004, respectively (P 5.309). Figure 4b-e shows the 5-year PFS for patients with renal tumors that measured <2 cm, from 2 cm to 4 cm, from 4 cm to 7 cm, and >7 cm. There were no significant differences in 5-year PFS with respect to tumor size over time. On univariate analysis (Table 2), factors that were associated with disease progression included patient race (P <.0001), tumor stage (P <.0001), Fuhrman tumor grade (P <.0001), tumor histology (P <.0001), type of operation (P <.0001), having undergone adrenalectomy (P <.0001), and having undergone lymphadenectomy (P <.0001). When significant variables were retained in a multivariate Cox regression analysis (Table 3), only tumor stage and Fuhrman tumor grade were associated with disease progression. Compared with patients who had T1 tumors, the odds of having disease progression were 4.5 for patients who had T2 tumors (95% confidence interval [95% CI], ; P <.0001), 2.3 for patients who had T3 tumors (95% CI, ; P 5.001), and 11.4 for patients who had T4 tumors (95% CI, ; P <.0001). Compared with patients who had Fuhrman grade 1 tumors, the odds of having disease progression were 2.7 for patients who had grade 3 tumors (95% CI, ; P 5.043) and 4.0 for patients who had grade 4 tumors (95% CI, ; P 5.015). There were no significant differences between the likelihood of disease progression for patients with grade 1 and grade 2 tumors. Figure 5a,b illustrates 5-year PFS according to tumor stage and Fuhrman grade, respectively. Overall Survival In total, 376 patients (23%) died from any cause after nephrectomy at a median follow-up of 50.4 months (interquartile range, 61.3 months). The actuarial 5-year OS rates after nephrectomy (Table 2) were 83%, 80%, 84%, and 79% for patients treated from 1989 to 1992, from 1993 to 1996, from 1997 to 2000, and from 2001 to 2004, respectively (P ). On univariate analysis (Table 2), factors that were associated with OS included patient age (P <.0001), tumor stage (P <.0001), Fuhrman tumor grade (P <.0001), tumor histology (P <.0001), type of operation (P ), having undergone adrenalectomy (P ), and having undergone lymphadenectomy (P ). When significant variables were retained in a multivariate Cox regression analysis (Table 4), only patient age and tumor stage were associated with OS. Patients aged 70 years were at greater odds of dying from any cause after renal surgery than patients aged <70 years. Compared with patients who had T1 tumors, the odds of dying from any cause were 1.7 for patients who had T2 tumors (95% CI, ; P 5.028), 1.4 for patients who had T3 tumors (95% CI, ; P 5.037), and 5.3 for patients who had T4 tumors (95% CI, ; P 5.001). Figure 6a,b illustrates 5-year OS according to patient age and tumor stage, respectively. DISCUSSION The treatment paradigm of surgically removing solid renal masses on detection recently has been questioned. Investigators have demonstrated that the rising incidence of kidney cancer in the past 20 years largely is attributable to the increased detection of small renal masses; and, despite parallel increases in surgical treatment, mortality rates for kidney cancer have continued to rise. 9 Furthermore, detection of advanced tumors, including those with regional involvement and distant metastasis, also has increased in incidence, calling into question whether incidental detection has had a positive impact on mortality and whether the increased detection of asymptomatic tumors by imaging procedures can explain fully the rising incidence trends of kidney cancer. 2,11 A prior study demonstrated that the greatest absolute increase in kidney cancer mortality is in patients with lesions >7 cm. Although cancer-specific mortality rates in that study also rose in patients who had tumors <2 cm, from 2 cm to 4 cm, and from >4 cm to 7 cm, the increases were not as pronounced as among patients who had lesions >7 cm. 9 However, other investigators have argued that survival rates, compared with mortality rates, should reflect more accurately the clinical course of patients after a cancer diagnosis. By using data from the Surveillance, Epidemiology, and End Results (SEER) Program, those investigators observed improved 5-year relative survival rates over time for patients with kid-
7 90 CANCER July 1, 2008 / Volume 113 / Number 1 FIGURE 4. (a) Progression-free survival (PFS) for the entire cohort of patients who presented with localized renal cortical tumors. (b) PFS for patients with renal tumors <2 cm. (c) PFS for patients with renal tumors 2 cm and 4 cm. (d) PFS for patients with renal tumors >4 cm and 7 cm. (e) PFS for patients with renal tumors >7 cm. Line A indicates 1989 through 1992; line B, 1993 through 1996; line C, 1997 through 2000; line D, 2001 through 2004.
8 Survival After Resection of Kidney CA/Russo et al. 91 FIGURE 4. (continued) ney cancer, particularly for patients with small tumors. 12 Similar to reported national trends, 9 we demonstrate a size migration toward smaller tumors (Fig. 1a) and an increasing number of nephrectomies performed from 1989 to 2004 (Fig. 2). Presumably, mortality rates from kidney cancer would be even higher if earlier and incidental detection were not so common. 2,11 However, survival rates did not improve or differ significantly over time at our institution (Fig. 4a). To account for these observed trends in PFS, we evaluated changes in tumor- and surgery-related fac-
9 92 CANCER July 1, 2008 / Volume 113 / Number 1 FIGURE 4. (continued) tors with respect to time. Whereas Fuhrman tumor grade (Fig. 3d) and histology (Fig. 3a) did not vary significantly over time, we observed a stage migration toward T1a lesions (Fig. 1b). Coincident with the favorable stage migration, the proportion of patients who underwent concomitant lymphadenectomy and adrenalectomy at the time of nephrectomy decreased significantly over time (Fig. 3b,c, respectively) when excluding historic data with incomplete ascertainment (ie, the cohort). The observable trends in tumor- and surgery-related characteristics with respect to time could not account for why PFS did not improve or differ significantly over time despite a favorable size migration and an increase in the number of operations performed. In contrast to survival data from the SEER Program, 12 it is conceivable that more advanced or aggressive tumors are being referred to tertiary care centers for management, that patients who were treated in more contemporary eras at our center had more stringent follow-up and, thus, increased attribution of death to kidney cancer than in the past, or that selection of indolent tumors for observation at tertiary care centers has led to more aggressive tumors presenting for surgery. This may account in part for the differences in 5-year survival rates observed in our data compared with data from the SEER Program. Finally, other unidentified factors may be contributory. For example, it is unclear whether certain environmental, metabolic, or epidemiologic factors, such as obesity, hypertension, smoking, or race, either alone or in a multivariate setting, may have had a negative influence on the biologic behavior of kidney cancers in the past 2 decades and whether patients with more comorbid conditions are more likely to be treated at tertiary care centers. Previously, we reported that, although body mass index was associated with a greater proportion of clear cell histology, comorbidity, and surgical morbidity, it did not have an adverse impact on OS or PFS. 13 Factors that were associated with the progression of disease after surgical resection included higher tumor stage and higher Fuhrman grade. Patient age, sex, race, tumor laterality, tumor histology, year of surgery, type of nephrectomy (radical vs partial), surgical margin status, or undergoing concomitant adrenalectomy or lymph node dissection were not associated with disease progression. Investigators previously noted sex differences in kidney cancer-specific survival after treatment. 14,15
10 Survival After Resection of Kidney CA/Russo et al. 93 TABLE 2 Univariate Analysis of Progression-free Survival and Overall Survival 5 Years After Resection for Localized Kidney Cancer at Memorial Sloan-Kettering Cancer Center According to Patient-related, Tumor-related, and Surgery-related Characteristics 5-year PFS 5-year OS Characteristic No. of patients No. of events % 95% CI P No. of events % 95% CI P Patient-related Age at surgery, y.8315 <.0001 < > Sex Men Women Race < White Black Other Tumor-related Tumor laterality Left Right Tumor classification <.0001 <.0001 T T T T Tumor grade <.0001 < Tumor histology <.0001 <.0001 Clear cell Papillary Chromophobe Unclassified Collecting duct Surgery-related Surgery y Type of surgery < Radical Partial Surgical margin status Negative Positive Adrenalectomy < No Yes Lymph node dissection < No Yes PFS indicates progression-free survival; OS, overall survival; 95% CI, 95% confidence interval.
11 94 CANCER July 1, 2008 / Volume 113 / Number 1 TABLE 3 Multivariate Analysis of Factors Associated With Disease Progression After Nephrectomy for Patients With Localized Kidney Cancer Patient characteristics No. of events OR (95% CI) P All patients 179 Race White (Referent) Black ( ).347 Other ( ).736 Tumor classification T (Referent) T ( ) <.0001 T ( ).001 T ( ) <.0001 Tumor grade (Referent) ( ) ( ) ( ).015 Tumor histology Clear cell (Referent) Papillary ( ).085 Chromophobe ( ).178 Unclassified ( ).02 Collecting duct 1 Type of surgery Radical nephrectomy (Referent) Partial nephrectomy ( ).337 Adrenalectomy No (Referent) Yes ( ).523 Lymph node dissection No (Referent) Yes ( ).068 OR indicates odds ratio; 95% CI, 95% confidence interval. On univariate analysis, we observed that, at 5 years after nephrectomy for localized disease, men were at no greater risk of developing disease progression than women (5-year PFS rate: 86% for men vs 91% for women; P ). However, this trend approached statistical significance; and, with longer follow-up, we may anticipate that men will be more likely to develop disease progression than women. The main factors that contribute to a less favorable prognosis in men are the higher proportion of advanced-stage disease and the higher proportion of higher grade disease in men compared with women. For instance, 64%, 9%, 26%, and 1% of men, compared with 70%, 10.6%, 19%, and 0.4% of women, had pathologic stage T1, T2, T3, and T4 tumors, respectively (P 5.009). Fuhrman grade 1, 2, 3, and 4 disease was identified in 7%, 63%, 26%, and 4% of men, respectively, compared with 11%, 70%, 17%, and 2% of women, respectively (P <.0001). FIGURE 5. (a) Progression-free survival according to pathologic tumor (pt) classification. Line A indicates pt1 tumors; line B, pt2 tumors; line C, pt3 tumors; line D, pt4 tumors. (b) Progression-free survival according to tumor grade. Line A indicates grade 1; line B, grade 2; line C, grade 3; line D, grade 4. Finally, 5-year OS did not differ for patients who were treated in more contemporary eras compared with historic cohorts (Table 2) and ranged from 79% to 84%. On multivariate analysis, patient age and tumor stage were the only factors associated with OS. Although it was beyond the scope of the current study, competing-cause mortality rises with increasing patient age for patients with renal masses 16 and must be taken into consideration during surgical planning and in the selection of appropriate candidates for active surveillance as the initial therapeutic approach for select tumors. Because comorbid conditions such as chronic kidney disease have been
12 Survival After Resection of Kidney CA/Russo et al. 95 TABLE 4 Multivariate Analysis of Factors Associated With Overall Survival After Nephrectomy for Patients With Localized Kidney Cancer Patient characteristic No. of events OR (95% CI) P All patients 374 Patient age, y < (Referent) ( ) ( ) ( ) ( ).003 > ( ) <.0001 Tumor classification T (Referent) T ( ).028 T ( ).037 T ( ).001 Tumor grade (Referent) ( ) ( ) ( ).001 Tumor histology Clear cell (Referent) Papillary ( ).493 Chromophobe ( ).094 Unclassified ( ).075 Collecting duct ( ).057 Type of surgery Radical nephrectomy (Referent) Partial nephrectomy ( ).492 Adrenalectomy No (Referent) Yes ( ).58 Lymph node dissection No (Referent) Yes ( ).842 OR indicates odds ratio; 95% CI, 95% confidence interval. associated with increased cardiovascular morbidity and mortality 17 and its prevalence in patients with renal cortical tumors has been reported to be higher than was believed previously, 18 maximal renal functional preservation is essential. Limitations of our study include selection bias associated with referrals to a tertiary care center, the retrospective nature of the review, and the finding that some patients remain at risk for a recurrence at a median follow-up of 50 months. Perhaps cancer-specific survival would have been a more meaningful clinical endpoint than PFS. However, given the relatively few events (n 5 68) available to evaluate cancer-specific survival and the finding that metastatic disease uniformly is deadly in this disease because of the lack of effective systemic therapies, the use of PFS as a proxy for kidney cancer mortality seems reasonable. FIGURE 6. (a) Overall survival according to patient age. Line A indicates aged <40 years; line B, ages 40 to 49 years; line C, ages 50 to 59 years; line D, ages 60 to 69 years; line E, ages 70 to 79 years; line F, aged 80 years. (b) Overall survival according to pathologic tumor (pt) classification. Line A indicates pt1 tumors; line B, pt2 tumors; line C, pt3 tumors; line D, pt4 tumors. The current study findings provide clues for further research into the prognosis for patients with kidney cancer who undergo surgery. Furthermore, the finding that PFS rates did not improve or differ significantly with time despite a favorable tumor size migration and increased numbers of nephrectomies performed requires further research to identify causative mechanisms and argues for the consideration of active surveillance for patients with select renal tumors and a re-evaluation of the current treatment paradigm of surgically removing solid renal masses on initial detection.
13 96 CANCER July 1, 2008 / Volume 113 / Number 1 REFERENCES 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, CA Cancer J Clin. 2007;57: Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281: Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100: Lee CT, Katz J, Shi W, Thaler HT, Reuter VE, Russo P. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 2000;163: Tsui KH, Shvarts O, Smith RB, Figlin R, de Kernion JB, Belldegrun A. Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol. 2000;163: Gudbjartsson T, Thoroddsen A, Petursdottir V, Hardarson S, Magnusson J, Einarsson GV. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology. 2005;66: Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients ( ). Urology. 2000; 56: Homma Y, Kawabe K, Kitamura T, et al. Increased incidental detection and reduced mortality in renal cancer recent retrospective analysis at 8 institutions. Int J Urol. 1995;2: Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98: Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; Hock LM, Lynch J, Balaji KC. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of Surveillance, Epidemiology and End Results Program data. J Urol. 2002;167: Chow WH, Linehan WM, Devesa SS. Re: rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2007;99: ; author reply Donat SM, Salzhauer EW, Mitra N, Yanke BV, Snyder ME, Russo P. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J Urol. 2006; 175: Onishi TT, Oishi YY, Goto HH, Yanada SS, Abe KK. Gender as a prognostic factor in patients with renal cell carcinoma. BJU Int. 2002;90: Beisland CC, Medby PCPC, Beisland HOHO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol. 2002;36: Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer. 2007;109: Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351: Huang WC, Levey AS, Serio AM, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 2006; 7:
BACKGROUND. Evidence exists to suggest a pattern of increasing early diagnosis
78 Renal Cell Cancer Stage Migration Analysis of the National Cancer Data Base Christopher J. Kane, MD 1,2 Katherine Mallin, PhD 3 Jamie Ritchey, MPH 3 Matthew R. Cooperberg, MD, MPH 4 Peter R. Carroll,
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationKIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA
KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA O.E. Stakhvoskyi, E.O. Stakhovsky, Y.V. Vitruk, O.A. Voylenko, P.S. Vukalovich, V.A. Kotov, O.M. Gavriluk National Canсer Institute,
More informationSignificant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell Carcinoma at a Private and Public Hospital in Brazil
Clinical Urology Heterogeneity to renal cell carcinoma International Braz J Urol Vol. 37 (5): 584-590, September - October, 2011 Significant Heterogeneity in terms of Diagnosis and Treatment of Renal Cell
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationIncidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study
Incidental Detection of Renal Cell Carcinoma is an Independent Prognostic Marker: Results of a Long-Term, Whole Population Study Helga Bjork Palsdottir, Sverrir Hardarson, Vigdis Petursdottir, Armann Jonsson,
More informationSecondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationMetastatic Renal Cell Carcinoma Risk According to Tumor Size
Metastatic Renal Cell Carcinoma Risk According to Tumor Size R. Houston Thompson, Jennifer R. Hill, Yuriy Babayev, Angel Cronin, Matt Kaag, Shilajit Kundu, Melanie Bernstein, Jonathan Coleman, Guido Dalbagni,
More informationOncological outcome of surgical treatment in 336 patients with renal cell carcinoma
窑 Original Article 窑 Chinese Journal of Cancer Oncological outcome of surgical treatment in 336 patients with renal cell carcinoma Zhi Ling Zhang,2, Yong Hong Li,2, Yong Hong Xiong 3, Guo Liang Hou,2,
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationA New Biomarker in Prostate Cancer Care: Oncotype Dx. David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY
A New Biomarker in Prostate Cancer Care: Oncotype Dx David M Albala, MD Chief of Urology Crouse Hospital Syracuse, NY Learning Objectives Review the current challenges in the prediction and prognosis of
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More informationThe Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney
Opposing Views The Management of a Clinical T1b Renal Tumor in the Presence of a Normal Contralateral Kidney NEPHRON SPARING SURGERY When a patient is seated in front of you with a6cm contrast enhancing
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More information4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective
Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light
More informationA912: Kidney, Renal cell carcinoma
A912: Kidney, Renal cell carcinoma General facts of kidney cancer Renal cell carcinoma, a form of kidney cancer that involves cancerous changes in the cells of the renal tubule, is the most common type
More informationIssues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
More informationProstate Cancer Screening in Taiwan: a must
Prostate Cancer Screening in Taiwan: a must 吳 俊 德 基 隆 長 庚 醫 院 台 灣 醫 學 會 105 th What is the PSA test? The blood level of PSA is often elevated in men with prostate cancer, and the PSA test was originally
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationHistorical Basis for Concern
Androgens After : Are We Ready? Mohit Khera, MD, MBA Assistant Professor of Urology Division of Male Reproductive Medicine and Surgery Scott Department of Urology Baylor College of Medicine Historical
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More informationCancer in Primary Care: Prostate Cancer Screening. How and How often? Should we and in which patients?
Cancer in Primary Care: Prostate Cancer Screening How and How often? Should we and in which patients? PLCO trial (Prostate, Lung, Colorectal and Ovarian) Results In the screening group, rates of compliance
More informationRenal cell carcinoma in India demonstrates early age of onset & a late stage of presentation
Indian J Med Res 140, November 2014, pp 624-629 Renal cell carcinoma in India demonstrates early age of onset & a late stage of presentation Shalini Agnihotri, Jatinder Kumar, Manoj Jain *, Rakesh Kapoor
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationRCC accounts for 3% of all malignant tumors and now
Prognostic Value of Thrombocytosis in Renal Cell Carcinoma Karim Bensalah, Emmanuelle Leray, Patricia Fergelot, Nathalie Rioux-Leclercq, Jacques Tostain, François Guillé and Jean-Jacques Patard* From the
More informationSurvival among Black and White Patients with Renal Cell Carcinoma in an Equal-Access Health Care System. Kangmin Zhu 1,4*
Survival among Black and White Patients with Renal Cell Carcinoma in an Equal-Access Health Care System Jie Lin 1*, Shelia H. Zahm 2, Craig D. Shriver 1,3,4, Mark Purdue 2, Katherine A. McGlynn 2, Kangmin
More informationUpdate on thyroid cancer surveillance and management of recurrent disease. Minimally invasive thyroid surgery
Update on thyroid cancer surveillance and management of recurrent disease Minimally invasive thyroid surgery July 2006 Michael W. Yeh, MD Program Director, Endocrine Surgery Assistant Professor, David
More informationObesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH
Obesity and prostate cancer incidence and survival Elizabeth A. Platz, ScD, MPH Professor and Martin D. Abeloff, MD Scholar in Cancer Prevention Department of Epidemiology, Johns Hopkins Bloomberg School
More informationJ Clin Oncol 23:6149-6156. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 25 SEPTEMBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Outcome Analysis for Patients With Elevated Serum Tumor Markers at Postchemotherapy Retroperitoneal Lymph Node
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationHow to treat early gastric cancer. Surgery
How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationCase Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)
More informationTranslocation Renal Cell Carcinomas
Translocation Renal Cell Carcinomas Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Kidney cancer is not a single disease Clear cell (75%)
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationSurvival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
More informationDoes Resection of an Intact Breast Primary Improve Survival in Metastatic Breast Cancer?
rvival in Metastatic Breast Cancer? Review Article [1] July 01, 2007 By Seema A. Khan, MD [2] The recommended primary treatment approach for women with metastatic breast cancer and an intact primary tumor
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationResearch Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma
Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,
More informationPARANEOPLASTIC SIGNS AND SYMPTOMS OF RENAL CELL CARCINOMA: IMPLICATIONS FOR PROGNOSIS
0022-5347/03/1705-1742/0 Vol. 170, 1742 1746, November 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000092764.81308.6a PARANEOPLASTIC
More informationDisparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance
Disparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance Acknowledgements and Disclaimer The collection of cancer incidence data used in this
More informationCarcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
More informationTravel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
More informationLouisiana Cancer Facts & Figures Kidney Cancer 2016
Louisiana Cancer Facts & Figures Kidney Cancer 2016 Louisiana Tumor Registry April 2016 1 Louisiana Tumor Registry Cancer Facts & Figures, Kidney Cancer 2016 Contents Contents: Table of Contents Introduction
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationProstate Cancer. Racial Differences in Prostate Cancer Treatment Outcomes. Prostate Cancer Epidemiology. Prostate Cancer Epidemiology
Prostate Cancer Anatomy Paul A. Godley, MD, PhD Cancer Incidence, Males Prostate Cancer Epidemiology 24 Estimated New Cancer Cases Melanoma 29,9 Oral 18,55 Stomach 13,4 Leukemias 19,2 Kidney 22,8 Lymphomas
More informationAre Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen
VOLUME 22 NUMBER 3 FEBRUARY 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen
More informationOutcome analysis of breast cancer patients who declined evidence-based treatment
Joseph et al. World Journal of Surgical Oncology 2012, 10:118 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Outcome analysis of breast cancer patients who declined evidence-based treatment Kurian
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationUnderstanding the. Controversies of. testosterone replacement. therapy in hypogonadal men with prostate cancer. controversies surrounding
Controversies of testosterone replacement therapy in hypogonadal men with prostate cancer Samuel Deem, DO CULTURA CREATIVE (RF) / ALAMY Understanding the controversies surrounding testosterone replacement
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationBRAF as a prognostic marker in papillary thyroid cancer
12 Congresso Nazionale AME Molecular markers in thyroid cancer: current role in clinical practice BRAF as a prognostic marker in papillary thyroid cancer Dott. ssa Cristina Romei Sezione di Endocrinologia
More informationPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
More informationRenal cell carcinoma and body composition:
Renal cell carcinoma and body composition: Results from a case-control control study Ryan P. Theis, MPH Department of Epidemiology and Biostatistics College of Public Health and Health Professions University
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationStage IV Prostate Cancer: Survival Differences in Clinical T4, Nodal and Metastatic Disease
Stage IV Prostate Cancer: Survival Differences in Clinical T4, Nodal and Metastatic Disease Wayland Hsiao,* Kelvin A. Moses,* Michael Goodman, Ashesh B. Jani,* Peter J. Rossi* and Viraj A. Master*, From
More informationEffective Health Care Program
Comparative Effectiveness Review Number 152 Effective Health Care Program Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer Executive Summary Background Nature and Burden of Nonmetastatic Muscle-Invasive
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationGuide to Biostatistics
MedPage Tools Guide to Biostatistics Study Designs Here is a compilation of important epidemiologic and common biostatistical terms used in medical research. You can use it as a reference guide when reading
More informationBeyond the PSA: Genomic Testing in Localized Prostate Cancer
Beyond the PSA: Genomic Testing in Localized Prostate Cancer Kelvin A. Moses, MD, PhD Vanderbilt University Medical Center Wednesday, December 2, 2015 5:00 p.m. ET/2:00 p.m. PT About ZERO ZERO s mission
More informationCHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal
CHILDHOOD CANCER SURVIVOR STUDY Analysis Concept Proposal 1. STUDY TITLE: Longitudinal Assessment of Chronic Health Conditions: The Aging of Childhood Cancer Survivors 2. WORKING GROUP AND INVESTIGATORS:
More informationRenal Pathology Update. Sundus Hussein MD, FRCPC
Renal Pathology Update Sundus Hussein MD, FRCPC Case History A 45 year old male with incidentally discovered a 3.5 x 3.9 x 2.7 cm renal mass Handling partial nephrectomy Handling partial nephrectomy
More informationCONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA
CONTEMPORARY MANAGEMENT OF RENAL ANGIOMYOLIPOMA Stephen A. Boorjian, MD Professor of Urology Vice Chair of Research Director, Urologic Oncology Fellowship Department of Urology Mayo Clinic, Rochester,
More informationColorectal Cancer Screening Behaviors among American Indians in the Midwest
JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University
More informationProstatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationACCEPTED MANUSCRIPT. Understanding the performance of active surveillance selection criteria in diverse urology practices
Understanding the performance of active surveillance selection criteria in diverse urology practices Scott R. Hawken BS*,1, Paul R. Womble MD*,1, Lindsey A. Herrel MD 1, Zaojun Ye MS 1, Susan M. Linsell
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationDetection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical
Summary. 111 Detection and staging of recurrent prostate cancer is still one of the important clinical problems in prostate cancer. A rise in PSA or biochemical recurrence (BCR) is the first sign of recurrent
More informationProstate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?
Prostate Cancer What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer? Stacy Loeb, Edward M. Schaeffer, Bruce J. Trock, Jonathan I. Epstein, Elizabeth B. Humphreys, and Patrick C.
More informationTable 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
More informationIn 2006 approximately 234,000 men were diagnosed with
Long-Term Survival in Men With High Grade Prostate Cancer: A Comparison Between Conservative Treatment, Radiation Therapy and Radical Prostatectomy A Propensity Scoring Approach Ashutosh Tewari,*, George
More informationAnalysis of Population Cancer Risk Factors in National Information System SVOD
Analysis of Population Cancer Risk Factors in National Information System SVOD Mužík J. 1, Dušek L. 1,2, Pavliš P. 1, Koptíková J. 1, Žaloudík J. 3, Vyzula R. 3 Abstract Human risk assessment requires
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationUnderstanding the Impact of Breast Reconstruction on the Surgical Decision-Making Process for Breast Cancer
489 Understanding the Impact of Breast Reconstruction on the Surgical Decision-Making Process for Breast Cancer Amy K. Alderman, MD, MPH 1,2 Sarah T. Hawley, PhD 2,3 Jennifer Waljee, MD 4 Mahasin Mujahid,
More informationLiver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco
Liver Transplantation for Hepatocellular Carcinoma John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco Hepatocellular Carcinoma HCC is the 5th most common
More informationIndividual Prediction
Individual Prediction Michael W. Kattan, Ph.D. Professor of Medicine, Epidemiology and Biostatistics, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Chairman, Department
More informationSmall Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
More informationGuidelines for Management of Renal Cancer
Guidelines for Management of Renal Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Versions 2 and 3 Section 5 updated bullets 5.3 and 5.4 Section 6 updated
More informationTreatment and Surveillance of Non- Muscle Invasive Bladder Cancer
Treatment and Surveillance of Non- Muscle Invasive Bladder Cancer David Josephson, MD FACS Fellowship Director, Urologic Oncology and Robotic Surgery Program Staging Most important in risk assessment and
More informationAn Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection
DOI: 10.1093/jnci/djr028 ARTICLE JNCI djr028 MA JOURNAL NAME Art. No. CE Code The Author 2011. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationthe risk of developing skeletal metastases or local recurrence.
Original Article SERUM PSA AND CLINICAL RECURRENCE AFTER RRP FOR LOCALIZED PROSTATE CANCER HAUKAAS et al. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence
More information